{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:34:19Z","timestamp":1793414059600,"version":"4.5.0"},"reference-count":51,"publisher":"American Association for Cancer Research (AACR)","issue":"12","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Mechanisms of acquired resistance to immune checkpoint inhibitors (ICI) are poorly understood. We leveraged a collection of 14 ICI-resistant lung cancer samples to investigate whether alterations in genes encoding HLA Class I antigen processing and presentation machinery (APM) components or interferon signaling play a role in acquired resistance to PD-1 or PD-L1 antagonistic antibodies. Recurrent mutations or copy-number changes were not detected in our cohort. In one case, we found acquired homozygous loss of B2M that caused lack of cell-surface HLA Class I expression in the tumor and a matched patient-derived xenograft (PDX). Downregulation of B2M was also found in two additional PDXs established from ICI-resistant tumors. CRISPR-mediated knockout of B2m in an immunocompetent lung cancer mouse model conferred resistance to PD-1 blockade in vivo, proving its role in resistance to ICIs. These results indicate that HLA Class I APM disruption can mediate escape from ICIs in lung cancer.<\/jats:p>\n                  <jats:p>Significance: As programmed death 1 axis inhibitors are becoming more established in standard treatment algorithms for diverse malignancies, acquired resistance to these therapies is increasingly being encountered. Here, we found that defective antigen processing and presentation can serve as a mechanism of such resistance in lung cancer. Cancer Discov; 7(12); 1420\u201335. \u00a92017 AACR.<\/jats:p>\n                  <jats:p>This article is highlighted in the In This Issue feature, p. 1355<\/jats:p>","DOI":"10.1158\/2159-8290.cd-17-0593","type":"journal-article","created":{"date-parts":[[2017,10,12]],"date-time":"2017-10-12T20:10:14Z","timestamp":1507839014000},"page":"1420-1435","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":768,"title":["Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer"],"prefix":"10.1158","volume":"7","author":[{"given":"Scott","family":"Gettinger","sequence":"first","affiliation":[{"name":"1Department of Medicine (Section of Medical Oncology), Yale University School of Medicine, New Haven, Connecticut."},{"name":"2Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jungmin","family":"Choi","sequence":"additional","affiliation":[{"name":"3Department of Genetics, Yale University School of Medicine, New Haven, Connecticut."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Hastings","sequence":"additional","affiliation":[{"name":"2Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Truini","sequence":"additional","affiliation":[{"name":"2Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ila","family":"Datar","sequence":"additional","affiliation":[{"name":"4Department of Pathology, Yale University School of Medicine, New Haven, Connecticut."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Sowell","sequence":"additional","affiliation":[{"name":"5Department of Immunobiology, Yale University School of Medicine, New Haven, Connecticut."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Wurtz","sequence":"additional","affiliation":[{"name":"2Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weilai","family":"Dong","sequence":"additional","affiliation":[{"name":"3Department of Genetics, Yale University School of Medicine, New Haven, Connecticut."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoping","family":"Cai","sequence":"additional","affiliation":[{"name":"4Department of Pathology, Yale University School of Medicine, New Haven, Connecticut."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Ann","family":"Melnick","sequence":"additional","affiliation":[{"name":"2Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor Y.","family":"Du","sequence":"additional","affiliation":[{"name":"5Department of Immunobiology, Yale University School of Medicine, New Haven, Connecticut."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Schlessinger","sequence":"additional","affiliation":[{"name":"2Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut."},{"name":"6Department of Pharmacology, Yale University School of Medicine, New Haven, Connecticut."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah B.","family":"Goldberg","sequence":"additional","affiliation":[{"name":"1Department of Medicine (Section of Medical Oncology), Yale University School of Medicine, New Haven, Connecticut."},{"name":"2Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Chiang","sequence":"additional","affiliation":[{"name":"1Department of Medicine (Section of Medical Oncology), Yale University School of Medicine, New Haven, Connecticut."},{"name":"2Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel F.","family":"Sanmamed","sequence":"additional","affiliation":[{"name":"5Department of Immunobiology, Yale University School of Medicine, New Haven, Connecticut."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Melero","sequence":"additional","affiliation":[{"name":"7CIMA and Clinica Universidad de Navarra, Pamplona, Spain."},{"name":"8Centro de Investigaci\u00f3n Biom\u00e9dica en red de Oncolog\u00eda CIBERONC, Madrid, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jackeline","family":"Agorreta","sequence":"additional","affiliation":[{"name":"7CIMA and Clinica Universidad de Navarra, Pamplona, Spain."},{"name":"8Centro de Investigaci\u00f3n Biom\u00e9dica en red de Oncolog\u00eda CIBERONC, Madrid, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis M.","family":"Montuenga","sequence":"additional","affiliation":[{"name":"7CIMA and Clinica Universidad de Navarra, Pamplona, Spain."},{"name":"8Centro de Investigaci\u00f3n Biom\u00e9dica en red de Oncolog\u00eda CIBERONC, Madrid, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Lifton","sequence":"additional","affiliation":[{"name":"3Department of Genetics, Yale University School of Medicine, New Haven, Connecticut."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soldano","family":"Ferrone","sequence":"additional","affiliation":[{"name":"9Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Kavathas","sequence":"additional","affiliation":[{"name":"2Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut."},{"name":"5Department of Immunobiology, Yale University School of Medicine, New Haven, Connecticut."},{"name":"10Department of Laboratory Medicine, Yale University School of Medicine, New Haven, Connecticut."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Rimm","sequence":"additional","affiliation":[{"name":"2Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut."},{"name":"4Department of Pathology, Yale University School of Medicine, New Haven, Connecticut."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan M.","family":"Kaech","sequence":"additional","affiliation":[{"name":"2Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut."},{"name":"5Department of Immunobiology, Yale University School of Medicine, New Haven, Connecticut."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt","family":"Schalper","sequence":"additional","affiliation":[{"name":"1Department of Medicine (Section of Medical Oncology), Yale University School of Medicine, New Haven, Connecticut."},{"name":"2Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut."},{"name":"4Department of Pathology, Yale University School of Medicine, New Haven, Connecticut."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy S.","family":"Herbst","sequence":"additional","affiliation":[{"name":"1Department of Medicine (Section of Medical Oncology), Yale University School of Medicine, New Haven, Connecticut."},{"name":"2Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut."},{"name":"6Department of Pharmacology, Yale University School of Medicine, New Haven, Connecticut."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katerina","family":"Politi","sequence":"additional","affiliation":[{"name":"1Department of Medicine (Section of Medical Oncology), Yale University School of Medicine, New Haven, Connecticut."},{"name":"2Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut."},{"name":"4Department of Pathology, Yale University School of Medicine, New Haven, Connecticut."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2017,12,4]]},"reference":[{"key":"2022060701534468000_bib1","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrclinonc.2016.25","article-title":"The future of cancer treatment: immunomodulation, CARs and combination immunotherapy","volume":"13","author":"Khalil","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"2022060701534468000_bib2","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","author":"Freeman","year":"2000","journal-title":"J Exp Med"},{"key":"2022060701534468000_bib3","doi-asserted-by":"crossref","first-page":"328rv4","DOI":"10.1126\/scitranslmed.aad7118","article-title":"PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations","volume":"8","author":"Zou","year":"2016","journal-title":"Sci Transl Med"},{"key":"2022060701534468000_bib4","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1084\/jem.20082492","article-title":"Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies","volume":"206","author":"Peggs","year":"2009","journal-title":"J Exp Med"},{"key":"2022060701534468000_bib5","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1200\/JCO.2014.58.3708","article-title":"Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer","volume":"33","author":"Gettinger","year":"2015","journal-title":"J Clin Oncol"},{"key":"2022060701534468000_bib6","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Eng J Med"},{"key":"2022060701534468000_bib7","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N Eng J Med"},{"key":"2022060701534468000_bib8","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Eng J Med"},{"key":"2022060701534468000_bib9","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet"},{"key":"2022060701534468000_bib10","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","author":"Reck","year":"2016","journal-title":"N Eng J Med"},{"key":"2022060701534468000_bib11","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"key":"2022060701534468000_bib12","doi-asserted-by":"crossref","first-page":"1215PD","DOI":"10.1093\/annonc\/mdw383.15","article-title":"Long-term outcomes with nivolumab (Nivo) vs docetaxel (Doc) in patients (Pts) with advanced (Adv) NSCLC: CheckMate 017 and CheckMate 057 2-y update","volume":"27","author":"Barlesi","year":"2016","journal-title":"Ann Oncol"},{"key":"2022060701534468000_bib13","first-page":"CT077","article-title":"Five-year follow-up from the CA209-003 study of nivolumab in previously treated advanced non-small cell lung cancer: clinical characteristics of long-term survivors","volume-title":"AACR Annual Meeting Abstract","author":"Brahmer","year":"2017"},{"key":"2022060701534468000_bib14","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1200\/JCO.2011.38.4032","article-title":"Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB\/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study","volume":"30","author":"Lynch","year":"2012","journal-title":"J Clin Oncol"},{"key":"2022060701534468000_bib15","doi-asserted-by":"crossref","first-page":"abstr 8071","DOI":"10.1200\/jco.2009.27.15_suppl.8071","article-title":"Randomized phase II clinical trial comparing tremelimumab (CP-675,206) with best supportive care (BSC) following first-line platinum-based therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC)","volume":"27","author":"Zatloukal","year":"2009","journal-title":"J Clin Oncol"},{"key":"2022060701534468000_bib16","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(16)30624-6","article-title":"Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study","volume":"18","author":"Hellmann","year":"2017","journal-title":"Lancet Oncol"},{"key":"2022060701534468000_bib17","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S1470-2045(15)00544-6","article-title":"Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study","volume":"17","author":"Antonia","year":"2016","journal-title":"Lancet Oncol"},{"key":"2022060701534468000_bib18","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science (New York, NY"},{"key":"2022060701534468000_bib19","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","article-title":"Genetic basis for clinical response to CTLA-4 blockade in melanoma","volume":"371","author":"Snyder","year":"2014","journal-title":"N Eng J Med"},{"key":"2022060701534468000_bib20","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1126\/science.aad0095","article-title":"Genomic correlates of response to CTLA-4 blockade in metastatic melanoma","volume":"350","author":"Van Allen","year":"2015","journal-title":"Science (New York, NY"},{"key":"2022060701534468000_bib21","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1158\/2159-8290.CD-16-0828","article-title":"Evolution of neoantigen landscape during immune checkpoint blockade in non-small cell lung cancer","volume":"7","author":"Anagnostou","year":"2017","journal-title":"Cancer Discov"},{"key":"2022060701534468000_bib22","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations associated with acquired resistance to PD-1 blockade in melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"N Eng J Med"},{"key":"2022060701534468000_bib23","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1158\/2159-8290.CD-16-1223","article-title":"Primary resistance to PD-1 blockade mediated by JAK1\/2 mutations","volume":"7","author":"Shin","year":"2017","journal-title":"Cancer Discov"},{"key":"2022060701534468000_bib24","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"2022060701534468000_bib25","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/ng.3564","article-title":"Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas","volume":"48","author":"Campbell","year":"2016","journal-title":"Nat Genet"},{"key":"2022060701534468000_bib26","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"key":"2022060701534468000_bib27","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1126\/science.aag0299","article-title":"Mutational signatures associated with tobacco smoking in human cancer","volume":"354","author":"Alexandrov","year":"2016","journal-title":"Science"},{"key":"2022060701534468000_bib28","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1609279","article-title":"T-cell transfer therapy targeting mutant KRAS in cancer","volume":"375","author":"Tran","year":"2016","journal-title":"N Eng J Med"},{"key":"2022060701534468000_bib29","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/jnci\/88.2.100","article-title":"Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy","volume":"88","author":"Restifo","year":"1996","journal-title":"J Nat Cancer Inst"},{"key":"2022060701534468000_bib30","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1172\/JCI114984","article-title":"Lack of HLA class I antigen expression by cultured melanoma cells FO-1 due to a defect in B2m gene expression","volume":"87","author":"D'Urso","year":"1991","journal-title":"J Clin Invest"},{"key":"2022060701534468000_bib31","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.jtho.2016.01.013","article-title":"Successful immunotherapy against a transplantable mouse squamous lung carcinoma with anti-PD-1 and anti-CD137 monoclonal antibodies","volume":"11","author":"Azpilikueta","year":"2016","journal-title":"J Thorac Oncol"},{"key":"2022060701534468000_bib32","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.molonc.2014.07.011","article-title":"Acquired and intrinsic resistance in cancer immunotherapy","volume":"8","author":"Kelderman","year":"2014","journal-title":"Mol Oncol"},{"key":"2022060701534468000_bib33","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.cell.2016.08.069","article-title":"Loss of IFN-gamma pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy","volume":"167","author":"Gao","year":"2016","journal-title":"Cell"},{"key":"2022060701534468000_bib34","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/ijc.28338","article-title":"Immune escape of cancer cells with beta2-microglobulin loss over the course of metastatic melanoma","volume":"134","author":"del Campo","year":"2014","journal-title":"Int J Cancer"},{"key":"2022060701534468000_bib35","doi-asserted-by":"crossref","first-page":"6593","DOI":"10.1158\/1078-0432.CCR-14-0567","article-title":"Genetic evolution of T-cell resistance in the course of melanoma progression","volume":"20","author":"Sucker","year":"2014","journal-title":"Clin Cancer Res"},{"key":"2022060701534468000_bib36","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1158\/1078-0432.CCR-05-2174","article-title":"The coincidence of chromosome 15 aberrations and beta2-microglobulin gene mutations is causative for the total loss of human leukocyte antigen class I expression in melanoma","volume":"12","author":"Paschen","year":"2006","journal-title":"Clin Cancer Res"},{"key":"2022060701534468000_bib37","doi-asserted-by":"crossref","first-page":"5869","DOI":"10.1038\/onc.2008.273","article-title":"HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance","volume":"27","author":"Campoli","year":"2008","journal-title":"Oncogene"},{"key":"2022060701534468000_bib38","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0065-230X(05)93006-6","article-title":"Classical and nonclassical HLA class I antigen and NK Cell-activating ligand changes in malignant cells: current challenges and future directions","volume":"93","author":"Chang","year":"2005","journal-title":"Adv Cancer Res"},{"key":"2022060701534468000_bib39","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1007\/s00262-012-1321-6","article-title":"Implication of the beta2-microglobulin gene in the generation of tumor escape phenotypes","volume":"61","author":"Bernal","year":"2012","journal-title":"Cancer Immunol Immunother"},{"key":"2022060701534468000_bib40","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/j.1399-0039.1998.tb03082.x","article-title":"Mutations of the beta2-microglobulin gene result in a lack of HLA class I molecules on melanoma cells of two patients immunized with MAGE peptides","volume":"52","author":"Benitez","year":"1998","journal-title":"Tissue Antigens"},{"key":"2022060701534468000_bib41","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/nature11126","article-title":"A tumour suppressor network relying on the polyamine-hypusine axis","volume":"487","author":"Scuoppo","year":"2012","journal-title":"Nature"},{"key":"2022060701534468000_bib42","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.ccell.2016.04.003","article-title":"Loss of chromosome 8p governs tumor progression and drug response by altering lipid metabolism","volume":"29","author":"Cai","year":"2016","journal-title":"Cancer Cell"},{"key":"2022060701534468000_bib43","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-16-1946-T","article-title":"Genomic profiling of patient-derived xenografts for lung cancer identifies B2M inactivation impairing immunorecognition","author":"Pereira","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2022060701534468000_bib44","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1016\/j.cell.2015.08.052","article-title":"Melanoma cell-intrinsic PD-1 receptor functions promote tumor growth","volume":"162","author":"Kleffel","year":"2015","journal-title":"Cell"},{"key":"2022060701534468000_bib45","doi-asserted-by":"crossref","first-page":"10501","DOI":"10.1038\/ncomms10501","article-title":"Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints","volume":"7","author":"Koyama","year":"2016","journal-title":"Nat Commun"},{"key":"2022060701534468000_bib46","doi-asserted-by":"crossref","first-page":"i172","DOI":"10.1093\/bioinformatics\/bts236","article-title":"Xenome\u2013a tool for classifying reads from xenograft samples","volume":"28","author":"Conway","year":"2012","journal-title":"Bioinformatics"},{"key":"2022060701534468000_bib47","doi-asserted-by":"crossref","first-page":"R36","DOI":"10.1186\/gb-2013-14-4-r36","article-title":"TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions","volume":"14","author":"Kim","year":"2013","journal-title":"Genome Biol"},{"key":"2022060701534468000_bib48","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1093\/bioinformatics\/btu638","article-title":"HTSeq\u2013a Python framework to work with high-throughput sequencing data","volume":"31","author":"Anders","year":"2015","journal-title":"Bioinformatics"},{"key":"2022060701534468000_bib49","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol"},{"key":"2022060701534468000_bib50","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1128\/JVI.01912-06","article-title":"The antiviral efficacy of simian immunodeficiency virus-specific CD8+ T cells is unrelated to epitope specificity and is abrogated by viral escape","volume":"81","author":"Loffredo","year":"2007","journal-title":"J Virol"},{"key":"2022060701534468000_bib51","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/nm.4100","article-title":"Impact of pre-adapted HIV transmission","volume":"22","author":"Carlson","year":"2016","journal-title":"Nat Med"}],"container-title":["Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/7\/12\/1420\/1838424\/1420.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/7\/12\/1420\/1838424\/1420.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T21:54:10Z","timestamp":1654552450000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/7\/12\/1420\/40352\/Impaired-HLA-Class-I-Antigen-Processing-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,1]]},"references-count":51,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2017,12,4]]},"published-print":{"date-parts":[[2017,12,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2159-8290.cd-17-0593","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/2159-8290.22532600","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.c.6546773.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22532597","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22532588","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22532591.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22532588.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22532594","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22532591","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22532597.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22532594.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22532600.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22532606.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22532606","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.c.6546773","asserted-by":"object"}]},"ISSN":["2159-8274","2159-8290"],"issn-type":[{"value":"2159-8274","type":"print"},{"value":"2159-8290","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,1]]}}}